Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced the release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, aimed at supporting immune cell- and stem cell-based therapy development and manufacturing. The system offers significant advantages over traditional lentivirus-based engineering methods, featuring a hyperactive enzyme capable of delivering multiple genes simultaneously while maintaining high editing efficiency.
The TcBuster system eliminates the need for viral clearance methods, reducing time to market and costs for cell therapy developers. It's compatible with various cell types, including immune cells and stem cells, and can be used for applications like autologous CAR-T, TCR manufacturing, allogeneic NK therapies, and engineering bioprocessing cell lines. Bio-Techne provides both RUO & GMP grade reagents with closed-system manufacturing options.
Positive
- Introduction of new GMP product expanding market opportunities in cell therapy development
- Technology offers cost and time reduction benefits compared to traditional methods
- Product features enhanced efficiency through hyperactive enzyme capabilities
- Strong and reliable supply chain for both RUO & GMP grade reagents
Negative
- None.
News Market Reaction
On the day this news was published, TECH declined 0.99%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene edited cell therapies, such as CAR-T or TCR generation.
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages.
"Our customers rely on us to help de-risk their cell therapy manufacturing programs and support their scale up to clinical trials and commercial manufacturing," said Will Geist, President Bio-Techne's Protein Science Segment. "Releasing a GMP version of our TcBuster non-viral genome engineering system marks a significant advance in meeting that goal, providing cell therapy developers with a powerful tool for efficient gene editing without the drawbacks of traditional viral delivery systems."
The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production.
The GMP TcBuster transposase is available now online at www.bio-techne.com/tcbuster. For more information on the TcBuster non-viral genome engineering system, please visit our website or contact us directly.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-release-of-gmp-tcbuster-non-viral-genome-engineering-system-302376063.html
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's new GMP TcBuster system and how does it impact cell therapy development?
How does TECH's TcBuster system differ from traditional lentivirus-based engineering methods?
What cell types are compatible with Bio-Techne's TcBuster system?
What are the key advantages of TECH's GMP TcBuster for cell therapy manufacturers?
